Charles Schwab Investment Management Inc. Raises Stock Position in Standard BioTools Inc. (NASDAQ:LAB)

Charles Schwab Investment Management Inc. grew its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 188.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,445,083 shares of the company’s stock after purchasing an additional 1,597,728 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Standard BioTools were worth $4,719,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Intech Investment Management LLC bought a new position in shares of Standard BioTools in the 3rd quarter valued at about $101,000. Royce & Associates LP lifted its stake in Standard BioTools by 102.0% in the third quarter. Royce & Associates LP now owns 614,552 shares of the company’s stock worth $1,186,000 after purchasing an additional 310,321 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Standard BioTools by 433.8% in the third quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock worth $35,000 after purchasing an additional 14,732 shares during the last quarter. Creative Planning bought a new stake in Standard BioTools in the third quarter worth about $39,000. Finally, SG Americas Securities LLC lifted its stake in Standard BioTools by 109.7% in the third quarter. SG Americas Securities LLC now owns 101,257 shares of the company’s stock worth $195,000 after purchasing an additional 52,970 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analysts Set New Price Targets

Separately, TD Cowen decreased their price objective on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.

Standard BioTools Stock Performance

Shares of NASDAQ:LAB opened at $1.91 on Friday. The firm has a market cap of $711.02 million, a PE ratio of -2.69 and a beta of 1.61. The firm’s 50 day simple moving average is $1.85 and its 200-day simple moving average is $1.96. Standard BioTools Inc. has a one year low of $1.21 and a one year high of $3.04.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.